EXAMINE, a trial evaluating the DPP-4 inhibitor alogliptin in patients with recent acute coronary syndrome, observed a neutral effect on cardiovascular outcomes, though the results suggested a non-significant trend toward increased heart failure risk. The gene discussed is DPP4; the disease is heart failure.